Evaluating Enoxaparin Use in Hospitalized COVID-19 Patients
Official title: Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
Run by Methodist Health System · NCT05226793 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study looks at how safe and effective different doses of enoxaparin are for hospitalized COVID-19 patients to see if it helps prevent blood clots and bleeding.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Richardson, Texas) |
| Trial ID | NCT05226793 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult patients hospitalized with COVID-19 who are receiving enoxaparin for DVT prophylaxis.
✕Probably not a fit
Patients who are not hospitalized or those not receiving enoxaparin for DVT prophylaxis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves a retrospective chart review of adult patients hospitalized with COVID-19 who received enoxaparin for DVT prophylaxis at Methodist Richardson Medical Center. The study aims to analyze the safety and effectiveness of different enoxaparin dosing regimens by examining various patient-specific factors and outcomes, including the incidence of DVT, PE, and bleeding events. Data will be collected from electronic health records and assessed for its impact on patient outcomes, with findings to be presented at a professional conference.
Why it matters
Potential benefit: If successful, this study could provide insights into optimal enoxaparin dosing for preventing thromboembolic events in COVID-19 patients.
How similar studies have gone: Other studies have explored anticoagulation strategies in COVID-19 patients, indicating potential for significant findings, though this specific evaluation is less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Effectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables: * Enoxaparin dose (appropriate for kidney function) * Charlson comorbidity index (CCI) score * Padua prediction score for risk of VTE * IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score * ICU status * Number of thromboembolic events * Length of stay * Readmissions for DVT and/or PE * In-hospital mortality with associated DVT or PE Exclusion Criteria: * Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables: * Bleeding events * Type of bleeding event
Where it's running
-
Methodist Richardson Medical Center
Richardson, Texas, United States Recruiting
Study contacts
- Principal investigator: Betina Daniel, PharmD — Methodist
- Study coordinator: Crystee Cooper, DHEd
- Email: clinicalresearch@mhd.com
- Phone: 214-947-1280
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
DoACs vs LMWH for blood flow after knee replacement
This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.
-
Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE
This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.
-
Screening for blood clots in adults with acute heart failure
This trial tests whether a guideline-based screening approach can detect pulmonary embolism in adults admitted with acute heart failure.
-
Blood test and software to guide treatment for venous thromboembolism
This project tests whether a blood-based ctDNA test combined with a software risk score can predict if VTE will come back in adults with cancer-associated DVT or PE who have finished 3–12 months of anticoagulation.
-
Aspiration thrombectomy with the Symphony or Prodigy devices
This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.
-
Combining European cohort data to find biomarkers that guide treatment for venous thromboembolism
This project combines clinical, biological and imaging data from European patient cohorts to try to find biomarkers that predict clot recurrence, bleeding, or death in people with venous thromboembolism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.